No Data
No Data
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
China Isotope & Radiation Bags Supply Project of Nuclear Medical Equipment in Nigeria
China Isotope & Radiation (HKG:1763) recently signed a contract for the overall supply project of nuclear medical equipment in Nigeria, a Tuesday filing on the Hong Kong bourse said.The project
CIRC Subsidiary Advances Cancer Treatment in China
Circ (01763): The new Gamma ray stereotactic radiotherapy system has successfully obtained the National Medical Products Administration's medical instrument registration certificate.
Circ (01763), a subsidiary of China National Nuclear Corporation, announced that its subsidiary, Zhongke Chengying (Xi'an) Medical Equipment Co., Ltd., ...
Express News | China Isotope & Radiation - Novel Gamma-Ray Stereotactic Radiotherapy System of Unit Obtained Medical Device Registration Certificate From Nmpa
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data